文献速递泌尿男性生殖肿瘤

基于PSMA-PET的新前列腺癌风险分组(PPP3):国际回顾性登记队列研究

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.
PubMed 文献 · Lancet Oncol · 2026-03-09

BACKGROUND: Prostate-specific membrane antigen (PSMA)-PET usage in patients with prostate cancer is growing rapidly. Thus, novel risk-group definitions based on PSMA-PET are urgently needed for guidelines, clinical use, and trial study design.…

要点

  • PPP3列线图基于PSMA-PET的PROMISE指标与临床疾病分组,可预测3/5/7年总生存。
  • 基于视觉列线图简化的风险分层表准确,便于临床全球推广使用。

核心结论

  • PPP3列线图与简化风险分层表可准确预测前列腺癌患者3年、5年和7年总生存。
  • PPP3评估不劣于或优于现有临床风险评分,且在线免费提供。

研究设计与样本

  • 国际回顾性登记队列研究,数据来自PROMISE PET登记库,35个研究中心按2:1分为开发队列(7253例)和验证队列(3901例)。
  • 纳入≥18岁经组织学证实的前列腺癌患者,任何疾病分期和体能状态,2012年12月6日至2024年6月26日接受PSMA-PET。
  • 排除神经内分泌模式或转移/播散性非前列腺癌恶性肿瘤患者。

主要发现

  • 两种列线图及简化风险分层表均准确,且不劣于或优于现有临床风险评分(STOPCAP、EAU、Gafita列线图、NCCN)。

关键数值与推荐

  • PPP3列线图基于Cox回归模型及LASSO惩罚构建,用于预测3年、5年和7年总生存。
  • 简化风险分层表基于视觉PPP3列线图创建。

临床怎么用

  • 可将PPP3列线图和简化风险分层表用于前列腺癌患者的风险分层和预后评估。
  • PROMISE和PPP3评估在线免费提供,便于全球临床推广。

局限性

  • 回顾性登记研究设计可能存在选择偏倚和残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA)-PET usage in patients with prostate cancer is growing rapidly. Thus, novel risk-group definitions based on PSMA-PET are urgently needed for guidelines, clinical use, and trial study design. We report improved risk classification based on PSMA-PET Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP) nomograms (PPP3) to prognosticate 3-year, 5-year, and 7-year overall survival. METHODS: In this international, retrospective, registry-based cohort study, we collected data from the PROMISE PET registry with ongoing overall survival follow-up. Male patients (aged ≥18 years) with histological proven prostate cancer at any disease stage and any performance status, who underwent any PSMA-PET between Dec 6, 2012, and June 26, 2024, were included in the registry. Patients with neuroendocrine pattern or metastasised or disseminated malignancy other than prostate cancer were excluded. 35 investigator sites in Europe, Asia, Australia, North America, and South America were split pairwise (2:1) into development and validation cohorts. Entire investigator sites were split pairwise according to their site characteristics (ie, number of patients per disease group, country, follow-up). The primary study objective was overall survival. PPP3 nomograms were created based on Cox regression models with least absolute shrinkage and selection operator penalty to prognosticate 3-year, 5-year, and 7-year overall survival. Calibration curves and Harrell's c indices were applied and head-to-head comparison with clinical risk scores separated for each disease subgroup was conducted. Based on the visual PPP3 nomogram, a simplified risk-stratification table was created. FINDINGS: We analysed 11 154 patients and 7253 were included in the development cohort and 3901 in the validation cohort. Median follow-up to censoring or death was 4·9 years (IQR 3·5-6·6). Clinical disease group and PROMISE metrics were combined into visual and quantitative PPP3 nomograms, respectively. C indices were 0·83 (95% CI 0·82-0·84) for the visual nomogram and 0·84 (0·82-0·85) for the quantitative nomogram. Both nomograms and the simplified risk stratification table were accurate and equal or superior compared with established clinical risk scores (International Staging Collaboration for Cancer of the Prostate, European Association of Urology, a nomogram defined by Gafita and colleagues, and National Comprehensive Cancer Network). INTERPRETATION: We present new risk nomograms by PROMISE along with a simple table to prognosticate 3-year, 5-year, and 7-year overall survival in prostate cancer. PROMISE and PPP3 assessments are freely available online for global implementation. FUNDING: German Research Foundation, Prostate Cancer Foundation, Innovative Health Initiative Joint Undertaking, Novartis, AstraZeneca, and Amgen.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Karpinski MJ, Civan C, Rauscher I, et al. New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. Lancet Oncol. 2026. PMID: 41819113. doi:10.1016/S1470-2045(26)00016-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。